#USA #Minneapolis #System #FLEX Vessel Prep #Flex Vascular

FLEX Vascular's Promising 12-Month Study Results

FLEX Vascular, based in Minneapolis, has recently made headlines with the announcement of the results from their FLEX FIRST AV Registry. This comprehensive 12-month study evaluates the efficacy of the FLEX™ Vessel Prep System in a real-world clinical setting, specifically targeting patients with dysfunctional hemodialysis access. The findings were presented at the prestigious Charing Cross (CX) Symposium in London by Dr. Ari Kramer, the study's National Principal Investigator and Chair of the Vascular Access Program at Spartanburg Regional Medical Center in South Carolina.

Background and Study Details

The FLEX FIRST AV Registry is a multi-center, prospective clinical study that enrolled 130 patients across four centers in the United States. The study aimed to reflect a diverse and high-risk population typical of real-world clinical scenarios. Focused on complex lesion types, the results effectively demonstrated the FLEX™ Vessel Prep System's improved safety, durability, and overall performance.

Key findings revealed zero serious adverse events (SAEs) recorded at 30 days, with only a minor complication rate of just 0.8%. The study reported that primary patency at 12 months for target lesions in cephalic arch areas reached an impressive 40%, almost doubling historical benchmarks for percutaneous transluminal angioplasty (PTA). Even more striking, there was a reported 100% secondary patency in arteriovenous grafts at 12 months, without any cases of access abandonment.

Impact on Clinical Practices

One remarkable outcome of using the FLEX system was a reduction of one interventional procedure per patient annually when employed alongside PTA. Dr. Ari Kramer emphasized the significance of these results, suggesting they represent a transformative shift in how vascular access interventions are approached. The findings particularly reflect the safety and effectiveness of this system, which could lead to fewer reinterventions and more durable outcomes, even in challenging anatomical scenarios.

The population involved in the study exhibited a high prevalence of comorbidities, which is particularly relevant for clinical applications. Approximately 64.6% of patients had diabetes, while 95.4% were hypertensive. Moreover, the study saw a significant representation of African American patients, accounting for nearly 60% of the enrolled individuals, underscoring the broad applicability of these findings across diverse demographics.

Understanding the FLEX™ Vessel Prep System

The innovation behind the FLEX™ Vessel Prep System lies in its Kinetic Endovascular Micro-Incision Creation (KEMIC) technology, which provides a mechanical, drug-free, and implant-free method to optimize vessel compliance prior to conventional angioplasty. This approach is designed to simplify interventions while enhancing safety and durability.

Dr. Jordan Knepper, Chief Medical Officer at FLEX Vascular, echoed the study's findings, promoting the FLEX system as part of a new care paradigm in access intervention that prioritizes improved safety, reduced need for reinterventions, and enhanced long-term outcomes without introducing unnecessary complexities.

Conclusion

As FLEX Vascular continues to advance endovascular solutions for arteriovenous access and peripheral vascular interventions, the FLEX™ Vessel Prep System stands out as a pioneering technology. The promising results from the FLEX FIRST AV Registry mark a significant development in the management of hemodialysis access, offering hope for improved patient care and outcomes in the vascular space.

FLEX Vascular, or VentureMed Group, Inc., is committed to pushing the boundaries of medical technology with a focus on optimizing patients' vascular access experiences. With the FLEX™ Vessel Prep System already receiving FDA clearance and CE Mark approval, the future of vascular interventions is looking increasingly bright.